References (+ to expand)
References: 1. ThinPrep 2000 System [instructions for use] MAN-02060-002, Rev. 002. Marlborough, MA: Hologic, Inc.; 2015. 2. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. https://seer.cancer.gov/statfacts/html/cervix.html. Accessed August 4, 2017. 3. Aptima Combo 2 assay [package insert]. 502446-IFU-PI, Rev. 002. San Diego, CA: Hologic, Inc.; 2017. 4. Aptima Mycoplasma genitalium assay [package insert]. AW-14170-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2017. 5. National Estimate Shows Not Enough Young Women Tested for Chlamydia [news release]. Atlanta, GA: Centers for Disease Control and Prevention; March 13, 2012. https://www.cdc.gov/nchhstp/newsroom/2012/stdconference2012pressrelease.html. Accessed August 4, 2017. 6. CDC. Chlamydia – CDC Fact Sheet (Detailed). https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm. Updated October 17, 2016. Accessed August 4, 2017. 7. CDC. Gonorrhea – CDC Fact Sheet (Detailed Version). https://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea-detailed.htm. Updated October 25, 2016. Accessed August 4, 2017. 8. CDC Sexually Transmitted Diseases Treatment Guidelines, 2015. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf. Accessed August 4, 2017. 9. Aptima Trichomonas vaginalis Assay [package insert]. 503684-IFU-PI, Rev. 001. San Diego, CA: Hologic Inc.; 2016. 10. CDC. Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States. http://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. Published February 13, 2013. Accessed August 4, 2017. 11. Vaginitis. ACOG Practice Bulletin No. 72. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2006;107:1195-206. 12. Clad A, et al. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2011;49(3):1071-1076. doi:10.1128/JCM.01674-10. 13. Cubie HA, et al. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol. 2014;67(6):458-463. doi:0.1136/jclinpath-2013-202014. 14. Cuschieri K, et al. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. J Clin Virol. 2014;59(2):104-108. doi:10.1016/j.jcv.2013.12.001. 15. Cuzick J, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913. doi:10.1038/bjc.2013.22. 16. Dockter J, et al. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45:S55-S61. doi:10.1016/S1386-6532(09)70009-5. 17. Eaton B, et al. Comparison of the Aptima HPV assay and the cobas HPV test in an ASC-US population. Poster presented at: 28th International Papillomavirus Conference; Nov. 30-Dec 6, 2012; San Juan, Puerto Rico. 18. Iftner T, et al. GAST:German Aptima Screening Trial. Comparison of Aptima and hc2 in routine screening in Germany. Presented at: EUROGIN Congress; July 8-11, 2012; Prague, Czech Republic. 19. Monsonego J, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-basedcytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691-701. doi:10.1002/ijc.25726. 20. Nieves L, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer.2013;23:513-518. doi: 10.1097/IGC.0b013e318280f3bc. 21. Ovestad IT, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123(2):278-283. doi:10.1016/j.ygyno.2011.07.024. 22. Ratnam S, et al. Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer. J Clin Microbiol. 2011;49(2):557-564. doi:10.1128/JCM.02147-10. 23. Reuschenbach M, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010;119(1):98-105. doi:10.1016/j.ygyno.2010.06.011. 24. Aptima HPV Assay [package insert]. AW-12820-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2015. [24% reduction in false positives found in table 13.] 25. Szarewski A, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3033-3042. doi:10.1158/1055-9965.EPI-08-0508. 26. Szarewski A, et al. Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study. J Clin Microbiol. 2012;50(6):1867-1873. doi:10.1128/JCM.00181-12. 27. Wu R, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer. 2010;20(8):1411-1414. doi:10.1111/IGC.0b013e3181f29547. 28. Stoler MH. HPV Testing in Cervical Cytology Practice: It’s All About Choice. Acta Cytol. 2005;49(2):117-119. doi:10.1159/000326117. 29. Centers for Disease Control and Prevention. HPV Signs and Symptoms. http://www.cdc.gov/hpv/signs-symptoms.html. Updated August 15, 2015. Accessed August 4, 2017. 30. Centers for Disease Control and Prevention. Human Papillomavirus. Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbook. 12th Ed. https://www.cdc.gov/vaccines/pubs/pinkbook/index.html Published 13th Edition (2015). Accessed August 4, 2017. 31. Tinelli A. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol. 2009;10(8)767-71. 32. Cuschieri K, et al. Human papillomavirus type specific DNA and RNA persistence–implications for cervical disease progression and monitoring. J Med Virol. 2004;73(1):65-70. doi:10.1002/jmv.20062. 33. Aptima HPV 16 18/45 Genotype Assay [package insert, AW-12821 Rev.001], San Diego, CA: Hologic, Inc.; 2015. 34. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. 2010;11(11):1048-56. doi:10.1016/S1470-2045(10)70230-8. 35. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056. 36. Anagrius C, et al. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect. 2005;81:458-62. doi:10.1136/sti.2004.012062. 37. Taylor-Robinson D, et al. Mycoplasma genitalium: from Chrysalis to Multicolored Butterfly. Clin Microbiol Rev. 2011;24(3):498-514. doi:10.1128/CMR.00006-11. 38. CDC. Sexually Transmitted Diseases and Treatment Guidelines: Mycoplasma genitalium. https://www.cdc.gov/std/tg2015/emerging.htm. Updated June 4,2015. Accessed August 4, 2017. 39. CDC. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae – 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6302a1.htm. Published March 14, 2014. Accessed August 4, 2017. 40. Aptima Zika Virus assay [package insert]. AW-15406, Rev. 002. San Diego, CA: Hologic, Inc.; 2016. 41. Aptima HSV 1 & 2 assay [package insert]. AW-15346-001, Rev. 001. San Diego, CA: Hologic, Inc.; 2016. 42. 2017 European guidelines for the management of genital herpes. http://www.iusti.org/regions/europe/pdf/2017/2017EuropeanGuidelineForManagementOfGenitalHerpes061216.pdf. Updated May 12, 2016 Accessed August 4, 2017. 43. Sexually Transmitted Infections Fact Sheet. World Health Organization.http://www.who.int/mediacentre/factsheets/fs400/en/. Updated January 2016. Accessed August 4, 2017. 44. Grove MK, et al. Genital Herpes in Pregnancy. http://emedicine.medscape.com/article/274874-overview#showall. Updated January 20, 2017. Accessed August 4, 2017. 45. CDC. Genital Herpes – CDC Fact Sheet. https://www.cdc.gov/std/herpes/stdfact-herpes.htm. Updated February 21, 2017. Accessed August 4, 2017. 46. Ratnam S, et al. Workflow and Maintenance Characteristics of Five Automated Laboratory Instruments for the Diagnosis of Sexually Transmitted Infections. J Clin Microbiol. 2014;52(7):2299-2304. doi:10.1128/JCM.03549-13. 47. Hologic, Inc. Data on File. 2017. 48. ThinPrep Pap Test Bibliography. http://healthdxs.com/view-published-data/. Hologic, Inc. Published 2010. Accessed August 4, 2017. 49. ThinPrep Imaging System [package insert]. 86093-001. Marlborough, MA: Hologic, Inc.; 2009. 50. ThinPrep 2000 [operator’s manual]. MAN-02585-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2014. 51. ThinPrep 5000 Processor [operator’s manual]. MAN-02203-001, Rev. 002. Marlborough, MA: Hologic, Inc.; 2016. 52. ThinPrep 5000 Autoloader [operator’s manual]. MAN-02574-001, Rev. 001. Marlborough, MA: Hologic, Inc.; 2016. 53. Limaye A, et al. Comparative analysis of conventional Papanicolaou tests and a fluid-based thin-layer method. Arch Pathol Lab Med. 2003;127:200-4. 54. Miller, et al. Implementation of the ThinPrep Imaging System in a High Volume Metropolitan Laboratory. Diag Cytopath. 2007;35:213-7. 55. ThinPrep Imager [operator’s manual]. MAN-04199-001, Rev. 002. Marlborough, MA: Hologic, Inc.; 2016. 56. Munson E, et al. Clinical Laboratory Assessment of Mycoplasma genitalium Transcription-Mediated Amplification Using Primary Female Urogenital Specimens. J Clin Microbiol. 2016;52(2): 432-438. doi:10.1128/JCM.02463-15. 57. Taylor-Robinson D, et al. Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24(3):498-514. doi:10.1128/CMR.00006-11.